ASCO GU 2022 | An AI biomarker to aid in the decision of treatment with ADT for localized prostate cancer

Andrew Armstrong, MD, MS, Duke Cancer Institute, Durham, NC, discusses one of the first biomarkers in localized prostate cancer. Many men with intermediate prostate cancer can be treated with radiotherapy alone but are offered androgen deprivation therapy (ADT) according to NCCN Guidelines. Dr Armstrong explains how the identification of a biomarker would enable the prevention of the castration and side effects of hormonal therapy. This was achieved via artificial intelligence (AI) machine learning biomarkers from pathology slides. An AI biomarker was identified suggesting approximately 60% of men could safely avoid ADT when treated with intensity-modulated radiation therapy (IMRT), whilst identifying the 40% who do require ADT. This biomarker holds the potential to aid in treatment decision making for this patient population and enable the avoidance of unnecessary treatment with ADT. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.